Thursday December 14, 2017
Mar-28-2011 06:40TweetFollow @OregonNews
Part 2 - FDA's Continual Responsibility for Making Our Children Into a Nation of Drug Addicts!Marianne Skolek Salem-News.com
Why are parents allowing this to happen?
(MYRTLE BEACH, S.C.) - I recently wrote an article regarding a severe problem on the east coast titled: "Flamingo Pipeline" from Florida to New York City- OxyContin Epidemic.
Every state in the U.S. -- as well as Canada -- has been fighting a war to keep our children from becoming a statistic in the OxyContin epidemic the FDA has allowed to become a runaway train in death.
Why is OxyContin allowed to be prescribed for "moderate" pain and not for "severe" pain only? Relatively painless effort on the part of the FDA to reclassify OxyContin -- which is compared to Heroin -- but they have been resistant to saving scores of lives -- many of these young lives. Has any government agency -- including the FDA -- questioned why OxyContin continues to be manufactured in outrageous and "deadly" quantities so that it finds its way on to our streets?
The FDA's "blind eye" does not end with OxyContin
In 1997, 5 million children were listed as using psychotropic drugs, Ritalin being among the most common. Ritalin use has increased by 700% since 1990. By the year 2000, it was prescribed for approximately 7 million children.
Attention Deficit Hyperactivity Disorder (ADHD) is diagnosed eight times more often in boys than in girls.
Of these diagnosed children, 90% use a stimulant to help control the disorder. 70% of children with ADHD are prescribed Ritalin. 20% use its counterpart, the generic form known as methylphenidate and an amphetamine known as Dexedrine.
Beginning in the 1960s, it was used to treat children with ADHD, or Attention Deficit Disorder (ADD), known at the time as hyperactivity or minimal brain dysfunction (MBD).
Production and prescription of methylphenidate rose significantly in the 1990s, especially in the United States, as the ADHD diagnosis came to be better understood and more generally accepted within the medical and mental health communities.
The benefits and cost effectiveness of methylphenidate, i.e. Ritalin long term are unknown due to a lack of research.
There is a lack of evidence of the effectiveness in the long term of beneficial effects of methylphenidate (Ritalin) with regard to learning and academic performance.
An analysis of the literature concluded that methylphenidate quickly and effectively reduces the signs and symptoms of ADHD in children under the age of 18 in the short term but found that this conclusion may be biased due to the high number of low quality clinical trials in the literature.
Some adverse effects of stimulant therapy may emerge during long-term therapy, but there is very little research of the long-term effects of stimulants.
The United States produces 90% of the world’s Ritalin. It produces, sells and distributes more methylphenidate than any other country worldwide. In addition to the United States, methylphenidate is frequently used in the United Kingdom and Germany.
It is used in many European countries, but in much smaller percentages than in the United States. Some countries don’t use the drug at all, such as Sweden, which has banned its use.
The FDA approved "Intuniv" - the first non-stimulant extended release medication for the treatment of ADHD in children. This means it can be administered in one daily dose and given in the morning or at night as a stand-alone medication or in conjunction with another ADHD drug to boost overall effectiveness. Because Intuniv is not a stimulant, parents can feel better knowing that their child is being treated with a medication that does not have addictive properties and is less likely to be abused since it is not a controlled substance.
In clinical trials, Intuniv has been shown to boost the effectiveness of treatment when combined with a stimulant, resulting in greater attention span and reduced levels of impulsivity and hyperactivity. One possible drawback, however, is that it has not been tested for extended use, beyond that of 8 to 10 weeks. For this reason, physicians who prescribe Intuniv must closely monitor patients to determine whether it continues to be a successful protocol for longer term management of ADHD symptoms.
At the present time, Intuniv’s longer term efficacy is unknown and will be determined by physicians who carefully monitor patients being treated and report associated outcomes. Shire, Intuniv’s biopharmaceutical developer, continues to focus their research on this drug’s long term use potential for maintenance of children with ADHD who need drug treatment in order to succeed academically -- as well as socially.
In early 1998, according to Taylor's lawsuit, Harris had taken Zoloft for two months, but soon became "obsessional." Harris became obsessed with homicidal and suicidal thoughts "within weeks" after he began taking Zoloft, according to Dr. Tracy. Due to his obsession with killing, Harris was switched to Luvox, which was in his system at the time of the shooting, according to his autopsy. The change from Zoloft to Luvox is like switching from Pepsi to Coke, Dr. Tracy said.
Has your child been kept safe by the FDA in the treatment of H1N1 (swine flu)?
The FDA warning on Tamiflu (in the treatment of H1N1 or "swine flu") states, “People with the flu, particularly children, may be at an increased risk of self-injury and confusion shortly after taking Tamiflu and should be closely monitored for signs of unusual behavior.” (See link below).
It was noted that some children were struck with psychosis, delusions, and paranoia – all in formerly normal children. The FDA issued a warning about Tamiflu's potential for producing skin rashes.
It wasn't until reports surfaced of more than 100 new cases of delirium, hallucinations and other abnormal psychiatric behavior in children treated with Tamiflu that the FDA changed course and required Roche, the company that makes the drug, to include a warning label cautioning patients, doctors and parents to look out for strange behavior in anyone taking the drug.
Dr. Frances Kelsey was a hero while working at the FDA on the dangerous drug,Thalidomide in the 1960's - see links below. Will there be a hero in 2011 at the FDA to end the message to our kids "take a pill" to succeed in a classroom and to be able to socialize with friends -- after all -- the pills to "perform academically and socially" are all approved by the FDA -- as dangerous as they are.
In 1979, Robert S. Mendelsohn, MD wrote a book entitled "Confessions of a Medical Heretic." Dr. Mendelsohn wrote "If your child is a little too peppy for his teacher to handle - your doctor may go too far and turn him into a drug dependent." It appears that Dr. Mendelsohn was ahead of his time -- maybe it's time for the FDA to recognize that our children are being taught at a very young age "to take a pill" -- with, in scores of cases, very deadly consequences.
Might be a good time for Dr. Hamburg to recognize that the FDA is not protecting our children -- the blinders need to come off their eyes -- and the billion dollar plus deep pockets of pharma have to be sewn shut -- so as not to intimidate the FDA to be continued partners in crime.
LP -- "To love another person is to see the face of God." from "Les Miserables" -- To the gift of friendship, love, encouragement, great dialogue, "multi-tasking" and being so proud of each other's continued journey in faith is not only seeing the face of God -- but knowing God is responsible for bringing us together.
Salem-News.com Reporter Marianne Skolek, is an Activist for Victims of OxyContin and Purdue Pharma throughout the United States and Canada. In July 2007, she testified against Purdue Pharma in Federal Court in Virginia at the sentencing of their three CEO's - Michael Friedman, Howard Udell and Paul Goldenheim - who pleaded guilty to charges of marketing OxyContin as less likely to be addictive or abused to physicians and patients. She also testified against Purdue Pharma at a Judiciary Hearing of the U.S. Senate in July 2007. Marianne works with government agencies and private attorneys in having a voice for her daughter Jill, who died in 2002 after being prescribed OxyContin, as well as the voice for scores of victims of OxyContin. She has been involved in her work for the past 8-1/2 years and is currently working on a book that exposes Purdue Pharma for their continued criminal marketing of OxyContin.
Marianne is a nurse having graduated in 1991 as president of her graduating class. She also has a Paralegal certification. Marianne served on a Community Service Board for the Courier News, a Gannet newspaper in NJ writing articles predominantly regarding AIDS patients and their emotional issues. She was awarded a Community Service Award in 1993 by the Hunterdon County, NJ HIV/AIDS Task Force in recognition of and appreciation for the donated time, energy and love in facilitating a Support Group for persons with HIV/AIDS.